Benzene and Acute Myeloid Leukemia: Causation and Risk Evidence

From General Health Awareness to Occupational Concern

The legacy of general health and science information has long provided a foundational understanding of how environmental factors can influence human well-being. Within this broad context, public health resources have historically emphasized the importance of recognizing hazardous substances and their potential to disrupt normal physiological processes. This heritage includes awareness of chemical exposures in everyday settings, from household products to ambient air quality, and the principle that sustained contact with certain agents may elevate disease risk. As this knowledge base matured, it became increasingly clear that specific occupational environments present unique challenges, where workers face higher concentrations and prolonged durations of exposure to industrial chemicals. The transition from general health education to occupational health concern is particularly evident when considering volatile organic compounds such as benzene. While the general public may encounter benzene through gasoline fumes or cigarette smoke, industrial settings—including chemical manufacturing, petroleum refining, and rubber production—involve routine handling of this solvent. This shift in focus from broad environmental awareness to targeted workplace exposure underscores the need for specialized risk assessment.

Epidemiological Evidence Linking Benzene to Acute Myeloid Leukemia

Benzene is a recognized human carcinogen, and a substantial body of epidemiological and mechanistic evidence links occupational and environmental exposure to an increased risk of acute myeloid leukemia (AML). This section reviews the key studies and biological pathways that establish benzene as a causal agent for AML, along with considerations regarding exposure timelines and the adequacy of warnings. Multiple large-scale cohort studies have demonstrated a consistent association between benzene exposure and AML. Occupational exposure to benzene at levels of 10 parts per million (ppm) or more has been associated with an increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). A meta-analysis of 25 studies found that benzene exposure was associated with an elevated risk of AML in children, with an odds ratio of 1.22 (95% confidence interval: 1.02–1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). In a national cohort from Switzerland, occupational benzene exposure was linked to elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). These findings reinforce the causal relationship between benzene and AML, as previous studies have established a causal link between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Mechanistic Pathways and Exposure Timeline

Benzene is acknowledged as a myelotoxin, and its carcinogenic ability has been reported to augment the risk for the onset of AML, myelodysplastic syndromes (MDS), aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action (MOA) for AML development includes multiple earlier key events, such as hematotoxicity and genetic toxicity in the peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would prevent the apical adverse outcomes of MDS and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Possible mechanisms of benzene initiation of hematological tumors include genotoxic effects, action on oxidative stress and inflammation, and provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, genetic alterations alone are insufficient to fully explain the onset of hematologic malignancies, and epigenetic effects—such as altered gene expression—are increasingly recognized as contributing factors (https://pubmed.ncbi.nlm.nih.gov/34069279/). The timeline from benzene exposure to the development of AML can vary, but the key event-informed risk models indicate that early hematotoxic and genotoxic changes can be observed in peripheral blood before the onset of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Chronic exposure to benzene is a risk element for hematological neoplasms, and the latency period between exposure and AML diagnosis can span years to decades, depending on exposure intensity and duration (https://pubmed.ncbi.nlm.nih.gov/34069279/). The Swiss National Cohort study linked occupational exposure to benzene with increased mortality from AML, suggesting that the harm may be fatal over the long term (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Causation Considerations and Warning Adequacy

For patients with AML who have a history of benzene exposure, causation considerations include the level and duration of exposure, the presence of early hematotoxic effects, and the exclusion of other risk factors. The established causal relationship between benzene and AML supports the plausibility of benzene as a contributing cause in individual cases (https://pubmed.ncbi.nlm.nih.gov/38727681/). However, the multifactorial nature of AML means that genetic susceptibility and other environmental factors may also play a role. Given the well-documented link between benzene and AML, warnings about the risks of benzene exposure are critical for prevention. Occupational exposure limits, such as those set by regulatory agencies, aim to reduce risk, but the evidence suggests that even low-level exposure may increase AML risk (https://pubmed.ncbi.nlm.nih.gov/41485753/). The adequacy of warnings depends on their dissemination to workers, consumers, and the public, as well as the enforcement of exposure limits. The key event-informed risk models emphasize that preventing early hematotoxic and genotoxic changes could prevent AML, highlighting the importance of early detection and intervention in exposed populations (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between benzene exposure and acute myeloid leukemia?

Benzene is a recognized human carcinogen, and extensive epidemiological evidence shows a consistent association between benzene exposure and an increased risk of acute myeloid leukemia (AML). Studies have found that occupational exposure to benzene at levels of 10 ppm or more is associated with elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). A meta-analysis also reported a dose-response relationship in children (https://pubmed.ncbi.nlm.nih.gov/41485753/).

How long after benzene exposure can AML develop?

The latency period between benzene exposure and AML diagnosis can range from years to decades, depending on exposure intensity and duration. Chronic exposure leads to early hematotoxic and genotoxic changes observable in peripheral blood before AML onset (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.